Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation

Current Pharmaceutical Design

Volumn 20, Issue 32, 2014, Pages 5180-5185

  Chang, Jane Pei Chen ^a,b   Lane, Hsien Yuan ^a,b   Tsai, Guochuan E ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

ADHD; Attention deficit hyperactivity disorder; Glutamate; Glycine; NMDA; Treatment

Indexed keywords

AMPHETAMINE; ATOMOXETINE; BENZOIC ACID; GLUTAMIC ACID; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SARCOSINE; TRICYCLIC ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLASPARTIC ACID;

ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; EXECUTIVE FUNCTION; HUMAN; IMPULSIVENESS; MENTAL PATIENT; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; ADOLESCENT; ADULT; ANIMAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG DESIGN; GLUTAMIC ACID; GLYCINE; HUMANS; IMPULSIVE BEHAVIOR; N-METHYLASPARTATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84923833291     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666140110115227     Document Type: Article

References (95)

1. [1] Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attentiondeficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128(5): 1007-22.
2. [2] Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57(11): 1442-51.
3. [3] Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2(2): 104-13.
4. [4] Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163(4): 716-23.
5. [5] Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990; 29(4): 546-57.
6. [6] Gau SS. Parental and family factors for attention-deficit hyperactivity disorder in Taiwanese children. Aust N Z J Psychiatry 2007; 41(8): 688-96.
7. [7] Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3-to 5-year follow-up survey. Pediatrics 1993; 92(2): 212-8.
8. [8] Hechtman L, Weiss G, Perlman T. Hyperactives as young adults: past and current substance abuse and antisocial behavior. Am J Orthopsychiatry 1984; 54(3): 415-25.
9. [9] Hodgkins P, Montejano L, Sasane R, Huse D. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord 2011; 13(2).
10. [10] Jensen PS, Shervette RE, 3rd, Xenakis SN, Richters J. Anxiety and depressive disorders in attention deficit disorder with hyperactivity: new findings. Am J Psychiatry 1993; 150(8): 1203-9.
11. [11] Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry 1997; 36(8): 1065-79.
12. [12] Wilens TE, Biederman J, Brown S, et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J Am Acad Child Adolesc Psychiatry 2002; 41(3): 262-8.
13. [13] Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 1992; 49(9): 728-38.
14. [14] Pliszka SR. Comorbidity of attention-deficit hyperactivity disorder and overanxious disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(2): 197-203.
15. [15] Lambert NM, Sandoval J. The prevalence of learning disabilities in a sample of children considered hyperactive. J Abnorm Child Psychol 1980; 8(1): 33-50.
16. [16] Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148(5): 564-77.
17. [17] Gau SS, Chong MY, Yang P, Yen CF, Liang KY, Cheng AT. Psychiatric and psychosocial predictors of substance use disorders among adolescents: longitudinal study. Br J Psychiatry 2007; 190: 42-8.
18. [18] Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45(6): 642-57.
19. [19] Newcorn JH. Risks and benefits of available treatments for adult ADHD. J Clin Psychiatry 2011; 72(3): e12.
20. [20] Ahmann PA, Theye FW, Berg R, Linquist AJ, Van Erem AJ, Campbell LR. Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics 2001; 107(1): E10.
21. [21] Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993; 32(2): 343-9.
22. [22] Quintana H, Cherlin EA, Duesenberg DA, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Clin Ther 2007; 29(6): 1168-77.
23. [23] Cruz MP. Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder. P T 2010; 35(8): 448-51.
24. [24] Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(1): 5-26.
25. [25] Surman CB, Hammerness PG, Petty C, et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry 2012.
26. [26] Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007; 32(6): 631-42.
27. [27] Fuster JM. The cognit: a network model of cortical representation. Int J Psychophysiol 2006; 60(2): 125-32.
28. [28] Curtis DR, Johnston GA. Amino acid transmitters in the mammalian central nervous system. Ergeb Physiol 1974; 69(0): 97-188.
29. [29] Rajan I, Cline HT. Glutamate receptor activity is required for normal development of tectal cell dendrites in vivo. J Neurosci 1998; 18(19): 7836-46.
30. [30] Tikhonova IG, Baskin, II, Palyulin VA, Zefirov NS. Computer simulation of the three-dimensional structure of the glutamate site of the NR2B subunit of the NMDA receptor. Dokl Biochem Biophys 2002; 382: 38-41.
31. [31] Papouin T, Ladepeche L, Ruel J, et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012; 150(3): 633-46.
32. [32] Tikhonova IG, Baskin, II, Palyulin VA, Zefirov NS, Bachurin SO. Structural basis for understanding structure-activity relationships for the glutamate binding site of the NMDA receptor. J Med Chem 2002; 45(18): 3836-43.
33. [33] Tamiz AP, Cai SX, Zhou ZL, et al. Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists. J Med Chem 1999; 42(17): 3412-20.
34. [34] Dannhardt G, Kohl BK. The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr Med Chem 1998; 5(4): 253-63.
35. [35] Cai SX, Zhou ZL, Huang JC, et al. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site. J Med Chem 1996; 39(17): 3248-55.
36. [36] Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995; 34(10): 1219-37.
37. [37] Tsukada H, Nishiyama S, Fukumoto D, Sato K, Kakiuchi T, Domino EF. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005; 30(10): 1861-9.
38. [38] Xu SJ, Chen Z, Zhu LJ, Shen HQ, Luo JH. Visual recognition memory is related to basic expression level of NMDA receptor NR1/NR2B subtype in hippocampus and striatum of rats. Acta Pharmacol Sin 2005; 26(2): 177-80.
39. [39] Yamada K, Nabeshima T. Interaction of BDNF/TrkB signaling with NMDA receptor in learning and memory. Drug News Perspect 2004; 17(7): 435-8.
40. [40] de Lima MN, Laranja DC, Bromberg E, Roesler R, Schroder N. Pre-or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005; 156(1): 139-43.
41. [41] Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179(1): 303-9.
42. [42] Lissek S, Gunturkun O. Maintenance in working memory or response selection? Functions of NMDA receptors in the pigeon "prefrontal cortex". Behav Brain Res 2004; 153(2): 497-506.
43. [43] Sakimura K, Kutsuwada T, Ito I, et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 1995; 373(6510): 151-5.
44. [44] Kadotani H, Hirano T, Masugi M, et al. Motor discoordination results from combined gene disruption of the NMDA receptor NR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit. J Neurosci 1996; 16(24): 7859-67.
45. [45] Tashiro A, Sandler VM, Toni N, Zhao C, Gage FH. NMDAreceptor-mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature 2006; 442(7105): 929-33.
46. [46] Forrest D, Yuzaki M, Soares HD, et al. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 1994; 13(2): 325-38.
47. [47] Facchinetti F, Ciani E, Dall'Olio R, Virgili M, Contestabile A, Fonnum F. Structural, neurochemical and behavioural consequences of neonatal blockade of NMDA receptor through chronic treatment with CGP 39551 or MK-801. Brain Res Dev Brain Res 1993; 74(2): 219-24.
48. [48] Facchinetti F, Dall'Olio R, Ciani E, Sparapani M, Virgili M, Contestabile A. Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats. Neuroscience 1994; 60(2): 343-53.
49. [49] O'Donoghue DL, Poff CR, Block JJ. Chronic neonatal N-methyl-D-aspartate receptor antagonism with MK-801 increases the number of corticospinal cells retained into adulthood in the rat. Neurosci Lett 1993; 158(2): 143-6.
50. [50] Virgili M, Facchinetti F, Ciani E, Contestabile A. Decreased excitotoxic sensitivity in the olfactory cortex of adult rats after neonatal NMDA blockade. Neuroreport 1994; 5(16): 2141-4.
51. [51] Gorter JA, Botterblom MH, Feenstra MG, Boer GJ. Chronic neonatal NMDA receptor blockade with MK-801 alters monoamine metabolism in the adult rat. Neurosci Lett 1992; 137(1): 97-100.
52. [52] Gorter JA, Brady RJ. NMDA receptor responses in adult hippocampal CA1 region after neonatal treatment with MK-801: comparison with NMDA receptor responses in the immature rat. Brain Res 1994; 665(1): 63-8.
53. [53] Gorter JA, Titulaer M, Bos NP, Huisman E. Chronic neonatal MK-801 administration leads to a long-lasting increase in seizure sensitivity during the early stages of hippocampal kindling. Neurosci Lett 1991; 134(1): 29-32.
54. [54] Munakata Y, Casey BJ, Diamond A. Developmental cognitive neuroscience: progress and potential. Trends Cogn Sci 2004; 8(3): 122-8.
55. [55] Carli M, Robbins TW, Evenden JL, Everitt BJ. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983; 9(3): 361-80.
56. [56] Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002; 163(3-4): 362-80.
57. [57] McGaughy J, Kaiser T, Sarter M. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav Neurosci 1996; 110(2): 247-65.
58. [58] Russell VA. Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder--the spontaneously hypertensive rat. Neurosci Biobehav Rev 2003; 27(7): 671-82.
59. [59] Lehohla M, Kellaway L, Russell VA. NMDA receptor function in the prefrontal cortex of a rat model for attention-deficit hyperactivity disorder. Metab Brain Dis 2004; 19(1-2): 35-42.
60. [60] Russell VA. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Behav Brain Res 2002; 130(1-2): 191-6.
61. [61] Rezvani AH, Kholdebarin E, Dawson E, Levin ED. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. Int J Neuropsychopharmacol 2008; 11(1): 63-70.
62. [62] Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43(11): 811-6.
63. [63] Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev 2006; 26(4): 379-95.
64. [64] Dalley JW, Mar AC, Economidou D, Robbins TW. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol Biochem Behav 2008; 90(2): 250-60.
65. [65] Murphy ER, Dalley JW, Robbins TW. Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task. Psychopharmacology (Berl) 2005; 179(1): 99-107.
66. [66] Mirjana C, Baviera M, Invernizzi RW, Balducci C. The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 2004; 29(9): 1637-47.
67. [67] Passetti F, Chudasama Y, Robbins TW. The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex 2002; 12(12): 1254-68.
68. [68] Ceglia I, Carli M, Baviera M, Renoldi G, Calcagno E, Invernizzi RW. The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. J Neurochem 2004; 91(1): 189-99.
69. [69] Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron 2011; 69(4): 680-94.
70. [70] Ballard TM, McAllister KH. The NMDA antagonist EAA 494 does not impair working memory in an operant DNMTP task in rats. Pharmacol Biochem Behav 2000; 65(4): 725-30.
71. [71] Willmore CB, Bespalov AY, Beardsley PM. Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate lever-press counts. Pharmacol Biochem Behav 2001; 69(3-4): 493-502.
72. [72] Szostak C, Tombaugh TN. Use of a fixed consecutive number schedule of reinforcement to investigate the effects of pimozide on behavior controlled by internal and external stimuli. Pharmacol Biochem Behav 1981; 15(4): 609-17.
73. [73] Berger DF, Sagvolden T. Sex differences in operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 1998; 94(1): 73-82.
74. [74] Takita M, Yokoi H, Mizuno T. NMDA receptor clustering in rat prefrontal cortex revealed by in vitro calcium macroimaging. Neuroreport 1997; 8(2): 551-3.
75. [75] Jensen V, Rinholm JE, Johansen TJ, et al. N-methyl-D-aspartate receptor subunit dysfunction at hippocampal glutamatergic synapses in an animal model of attention-deficit/hyperactivity disorder. Neuroscience 2009; 158(1): 353-64.
76. [76] Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 2001; 21(2): 750-7.
77. [77] Kutsuwada T, Sakimura K, Manabe T, et al. Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Neuron 1996; 16(2): 333-44.
78. [78] Tang YP, Shimizu E, Dube GR, et al. Genetic enhancement of learning and memory in mice. Nature 1999; 401(6748): 63-9.
79. [79] Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA 2001; 98(20): 11047-54.
80. [80] Perlov E, Philipsen A, Hesslinger B, et al. Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder--a magnet resonance spectroscopy study. J Psychiatr Res 2007; 41(11): 934-41.
81. [81] Carrey N, MacMaster FP, Fogel J, et al. Metabolite changes resulting from treatment in children with ADHD: a 1H-MRS study. Clin Neuropharmacol 2003; 26(4): 218-21.
82. [82] Dorval KM, Wigg KG, Crosbie J, et al. Association of the glutamate receptor subunit gene GRIN2B with attentiondeficit/hyperactivity disorder. Genes Brain Behav 2007; 6(5): 444-52.
83. [83] Fisher SE, Francks C, McCracken JT, et al. A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am J Hum Genet 2002; 70(5): 1183-96.
84. [84] Dohmen C, Kumura E, Rosner G, Heiss WD, Graf R. Extracellular correlates of glutamate toxicity in short-term cerebral ischemia and reperfusion: a direct in vivo comparison between white and gray matter. Brain Res 2005; 1037(1-2): 43-51.
85. [85] Yu D, Duan Y, Bao Y, Wei C, An L. Isoflavonoids from Astragalus mongholicus protect PC12 cells from toxicity induced by L-glutamate. J Ethnopharmacol 2005; 98(1-2): 89-94.
86. [86] Kihara T, Sawada H, Nakamizo T, et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004; 325(3): 976-82.
87. [87] Kabadere S, Oztopcu P, Korkmaz S, Erol K, Uyar R. MgSO4 and lazaroid (U-83836E) partially protects glioma cells against glutamate toxicity in vitro. Acta Neurobiol Exp (Wars) 2004; 64(4): 461-6.
88. [88] Lin Y, Desbois A, Jiang S, Hou ST. P2 receptor antagonist PPADS confers neuroprotection against glutamate/NMDA toxicity. Neurosci Lett 2005; 377(2): 97-100.
89. [89] Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or Dserine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005; 62(11): 1196-204.
90. [90] Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 2012; 100(4): 665-77.
91. [91] Fukui K, Miyake Y. Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. J Biol Chem 1992; 267(26): 18631-8.
92. [92] Hashimoto K, Fujita Y, Horio M, et al. Co-administration of a Damino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 2009; 65(12): 1103-6.
93. [93] Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49(3): 206-15.
94. [94] Ornitz EM, Hanna GL, de Traversay J. Prestimulation-induced startle modulation in attention-deficit hyperactivity disorder and nocturnal enuresis. Psychophysiology 1992; 29(4): 437-51.
95. [95] VandenBerghe-Snorek S, Stankovich MT. Thermodynamic control of D-amino acid oxidase by benzoate binding. J Biol Chem 1985; 260(6): 3373-9.